Phase I Trial of Concurrent Twice-Weekly Recombinant Human Interleukin-12 Plus Low-Dose IL-2 in Patients With Melanoma or Renal Cell Carcinoma Purpose: Response of solid malignancies to therapy is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback